Key result
SPR biosensor accurately quantifies bevacizumab and correlates strongly with standard ELISA.
Why the study?
Does a surface plasmon resonance biosensor accurately quantify bevacizumab in human serum compared to ELISA?
Does a surface plasmon resonance biosensor accurately quantify bevacizumab in human serum compared to ELISA?
An SPR biosensor provides a simpler, faster, and smaller-volume alternative to ELISA for the therapeutic drug monitoring of bevacizumab.
May support simpler bevacizumab TDM; leaves open clinical adoption pending larger validation studies.
. Intra-day and inter-day precision showed a coefficient of variation (CV) below 15% and an accuracy ranging between 85% and 115%. Finally, the biosensor was successfully applied to 15 clinical serum samples, showing significant correlation with the ELISA results. Compared to traditional methods, the SPR biosensor offers simpler preparation, faster analysis, and smaller sample volumes, which provides a new option for the TDM of bevacizumab.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2025) studied this question. Surface plasmon resonance (SPR) biosensor vs. ELISA was evaluated on Quantification of bevacizumab (precision and accuracy). A surface plasmon resonance biosensor for quantifying bevacizumab demonstrated a CV <15% and accuracy of 85-115%, showing significant correlation with ELISA in 15 clinical serum samples.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: